Clinical Trials Sponsored by AM-Pharma

Total 8328 results

LEO Pharma

Terminated

A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp

Actinic Keratosis | Squamous Cell Carcinoma

United States, Spain, Canada, Germany, France, United Kingdom
LEO Pharma

Completed

LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

France
Kibow Pharma

Completed

Pilot-Scale Clinical Trials of Kibow Biotics® in Chronic Kidney Failure (Probiotics)

Chronic Kidney Failure

United States
PLx Pharma

Completed

Pharmacokinetic and Pharmacodynamic Assessment of a Novel, Pharmaceutical Lipid-Aspirin Complex

Bioequivalence
LEO Pharma

Completed

Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris

Psoriasis Vulgaris

Canada
UCB Pharma

Completed

Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis

Psoriasis

France, Germany
UCB Pharma

Completed

Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy

Chronic Plaque Psoriasis

France, Germany
LEO Pharma

Completed

Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively

Actinic Keratosis

United States
UCB Pharma

Completed

A Multicenter, Open-Label Study To Investigate The Safety And Pharmacokinetics Of Lacosamide In Children With Partial Seizures

Epilepsy

United States, Belgium, Mexico
Inventiva Pharma

Completed

Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis (FASST)

Scleroderma, Diffuse | Diffuse Cutaneous Systemic Sclerosis

United Kingdom, France, Spain, Switzerland, Italy, Slovenia, Netherlands, Germany, Bulgaria, Poland
LEO Pharma

Completed

Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis

Actinic Keratosis

United States
Innate Pharma

Completed

Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR) (EFFIKIR)

Acute Myeloid Leukemia

France
LEO Pharma

Completed

Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis

Psoriasis Vulgaris

Germany
LEO Pharma

Completed

Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis

Psoriasis Vulgaris

United States, Netherlands, Poland, Romania
LEO Pharma

Completed

A Study Comparing LEO 80190 Ointment With Hydrocortisone Ointment, Both Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and Intertriginous Areas

Psoriasis Vulgaris

France
LEO Pharma

Completed

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up

Actinic Keratosis

Germany
LEO Pharma

Completed

A Proof of Concept Study Comparing Three Doses of an Oral Solution of LEO 22811 With a Placebo Oral Solution for the Treatment of Psoriasis Vulgaris

Psoriasis Vulgaris

Canada, France
LEO Pharma

Completed

Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis

Actinic Keratosis

United States
LEO Pharma

Completed

Dermatopharmacokinetic Trial of LEO 80185 Gel

Psoriasis Vulgaris

Japan
UCB Pharma

Completed

Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus (EMBODY4)

Systemic Lupus Erythematosus

United States, Brazil, Canada, France, Germany, Hungary, Italy, Mexico, Poland, Romania, Russian Federation, South Africa, Spain, Ukraine, United Kingdom, Australia, Belgium, Bulgaria, Czechia, Estonia, Israel, Korea, Republic of, T... and more
LEO Pharma

Completed

Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest

Actinic Keratosis

United States
UCB Pharma

Completed

Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (EMBODY1)

Systemic Lupus Erythematosus

United States, Australia, Belgium, Brazil, Bulgaria, Czechia, Estonia, France, Germany, India, Israel, Italy, Korea, Republic of, Lithuania, Mexico, Puerto Rico, Romania, Russian Federation, Spain, Taiwan, United Kingdom
Kiomed Pharma

Unknown

sAfety PerfoRmance chitOsan osteOarthritis ViscosupplEmentation (APROOVE)

Knee Osteoarthritis
UCB Pharma

Completed

Transdermal Rotigotine User Surveillance Study (TRUST)

Idiopathic Parkinson Disease

Czechia, Denmark, Germany, Greece, Italy, Mexico, Romania, Slovakia, Spain, Switzerland
UCB Pharma

Terminated

A 12 Week Study to Assess Changes in Joint Inflammation Using Ultrasonography in Patients With Rheumatoid Arthritis (RA) (SWIFT)

Rheumatoid Arthritis

United States
UCB Pharma

Completed

A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis Subjects (PREDICT)

Rheumatoid Arthritis

United States
UCB Pharma

Completed

Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset Seizures

Epilepsy

United States, Australia, Canada, Denmark, Germany, Italy, Poland, United Kingdom, Spain
UCB Pharma

Completed

Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures

Epilepsy

United States, Argentina, Australia, Belgium, Bulgaria, Colombia, Croatia, Czechia, Estonia, Georgia, Hungary, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Mexico, Montenegro, Poland, Romania, Russian Federation, Serbia, Sl... and more
UCB Pharma

Completed

To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures

Partial Epilepsies

United States, Poland, United Kingdom, Switzerland, Hungary, Germany, Sweden, Lithuania
UCB Pharma

Completed

A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy

Diabetic Neuropathy

United States
UCB Pharma

Completed

Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures

Partial Epilepsies

United States, Austria, Bulgaria, Czechia, Denmark, Finland, France, Greece, Italy, Mexico, Romania, Russian Federation, Spain, Switzerland, Turkey
pH Pharma

Completed

PK/PD, Safety and Tolerability of PHP-201 Topical Eye Drop in Korean and Japanese Healthy Subjects

Healthy Volunteer

Korea, Republic of
UCB Pharma

Terminated

A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures

Epilepsy

United States, Belgium, Canada, Germany, Sweden, Czechia, Australia
UCB Pharma

Completed

Trial to Assess Optimized Dosage of Lacosamide as add-on Therapy in Patients With Partial Onset Seizure (SELF)

Partial Epilepsies

France
Horus Pharma

Completed

Evaluation of the Efficacy and Safety of DM05 Versus Optive™ on the Treatment of Moderate to Severe Ocular Dryness

Dry Eye
LEO Pharma

Completed

Biological Effects of LEO 43204 in Actinic Keratosis

Actinic Keratosis

United States
MaaT Pharma

Completed

InterventiOnal Study of Bone and Joint Infections Related Gut dysbiosIS (OSIRIS)

Bone and Joint Infection

France
UCB Pharma

Completed

Effect on RLS Symptom Severity After Switching to Neupro® in Patients Who Previously Experienced Augmentation (AURORA)

Restless Legs Syndrome

Germany
Zealand Pharma

Completed

Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects

Healthy Subjects

United States
LEO Pharma

Completed

Real-life Evaluation of the Daivobet® Gel Applicator (ASAP PSO)

Plaque Psoriasis

France
LEO Pharma

Completed

LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris

Psoriasis Vulgaris

Germany
Cardeas Pharma

Completed

Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative Pneumonia (IASIS)

Pneumonia, Bacterial

Spain, United States, Greece, Hungary, Turkey, Puerto Rico, France
LEO Pharma

Completed

An Exploratory Trial Investigating the Neurogenic Component in Psoriasis Vulgaris by Use of Botulinum Toxin A

Psoriasis Vulgaris

Denmark
LEO Pharma

Completed

An Explorative Trial Evaluating the Effect of LEO 32731 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)

Atopic Dermatitis

Germany
LEO Pharma

Completed

A Clinical Trial to Assess the Potential of LEO 130852A Gel to Reduce Steroid Induced Skin Atrophy on Healthy Skin

Connective Tissue Diseases | Skin Tissue Diseases

Germany
LEO Pharma

Terminated

A Phase I Study With LEO 32731 and Midazolam in Healthy Male Subjects

Psoriasis Vulgaris

United Kingdom
LEO Pharma

Completed

Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use Conditions

Actinic Keratosis

United States
LEO Pharma

Completed

A Single-Centre Clinical Trial to Assess Steroid Induced Skin Atrophy on Healthy Skin

Skin and Connective Tissue Diseases

Germany
LEO Pharma

Completed

LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)

Psoriasis Vulgaris

United States
LEO Pharma

Completed

LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

United States

3

Subscribe